MétaCan
Menu
Back to cohort
Record W4417297699 · doi:10.1111/bcpt.70176

Perspectives on the Influence of Pharmaceutical and MedTech Companies on Deprescribing Decisions and Conference Sponsorship: A Survey Study

2025· article· en· W4417297699 on OpenAlexaff
Katharina Tabea Jungo, Cynthia M. Boyd, Barbara Farrell, Caroline McCarthy

Bibliographic record

VenueBasic & Clinical Pharmacology & Toxicology · 2025
Typearticle
Languageen
FieldPharmacology, Toxicology and Pharmaceutics
TopicPharmaceutical industry and healthcare
Canadian institutionsBruyèreUniversity of Ottawa
FundersRoyal College of Surgeons in IrelandNational Institutes of HealthSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungNational Science Foundation
KeywordsDeprescribingSkepticismSurvey researchQuestionnaire

Abstract

fetched live from OpenAlex

BACKGROUND: The involvement and sponsorship of pharmaceutical and medical technology (MedTech) companies in deprescribing and medication optimization activities raise questions about conflicts of interest. We surveyed registrants and attendees of previous International Conferences on Deprescribing to explore views on the acceptability and impact of such involvement and sponsorship. METHODS: We conducted two unlinked, anonymous cross-sectional surveys among all participants of the 2022 and 2024 International Conferences on Deprescribing (376 unique email addresses). The first survey addressed pharmaceutical companies; the second focused on MedTech. Quantitative data were analysed descriptively. Free-text responses were analysed thematically. FINDINGS: The response rate was 33% (n = 116/355) for the pharmaceutical survey and 20% (n = 68/335) for the MedTech survey. Trust in deprescribing information was low for pharmaceutical companies, with 52% reporting distrust (n = 47/91). Trust was somewhat higher for MedTech companies, with 27% expressing distrust (n = 14/52). Forty-eight percent (n = 42/87) said they would be less likely to attend an international deprescribing conference with pharmaceutical sponsorship versus 26% (n = 13/49) for MedTech. Among clinicians and clinician-scientists who completed the survey, 27% (n = 18/67) said pharmaceutical companies, and 27% (n = 10/37) said MedTech companies, somewhat or very much influence their deprescribing decisions. CONCLUSIONS: Despite broad scepticism about private-sector involvement and sponsorship of deprescribing activities, views varied.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.008
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow), Science and technology studies, Research integrity, Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.128
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0120.008
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0010.004
Scholarly communication0.0000.000
Open science0.0010.001
Research integrity0.0010.006
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.618
GPT teacher head0.611
Teacher spread0.008 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBasic & Clinical Pharmacology & ToxicologySame topicPharmaceutical industry and healthcareFrench-language works237,207